《大行報告》中金:石藥(01093.HK)三代EGFR商業授權項目落地 升目標價至12元
中金發表研究報告指,石藥集團(01093.HK)獲上海倍而達藥業BPI-7711膠囊(三代EGFR)在國內的獨家產品授權和商業化權利,並得到BPI-1178膠囊商業化授權優先談判權,預期將進一步加強腫瘤創新管線。
報告指出,中國每年肺癌新發病患者約73萬人,其中非小細胞肺癌佔約85%,EGFR基因突變率約為40%,預期隨著一線適應症納入醫保及更多國產產品上市,國內三代EGFR藥物有望取代一、二代EGFR藥物,市場容量達到逾百億元人民幣。
中金表示,上海倍爾達的BPI-7711膠囊目前處於臨床3期及2b期,並將於近期在中國提交上市申請,有望成為第5家獲批上市的三代EGFR產品,維持對石藥2020至2021年每股盈利預測為0.38及0.43元人民幣,新增明年預測為每股0.49元人民幣,並維持「跑贏行業」評級,目標價升至12元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.